VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

VALCHLOR Support for you and your patients

Comprehensive support and resources are available throughout the
VALCHLOR treatment journey

For physicians and office staff icon

  • For physicians and office staff:

  • Patient support materials
    (eg, disease education and product information)
  • Assistance with insurance verification, prior authorization, and appeals

For patients and caregivers icon

  • For patients and caregivers:

  • Help with understanding what to expect with VALCHLOR gel
  • Ongoing educational resources about living with MF‑CTCL
  • Financial assistance for eligible patients
  • Prescription management assistance and advice

Self-administered therapy, delivered directly to wherever patients are located.
(Direct shipping is available from a specialty pharmacy for patient convenience.)

Available resources for you and your patients

VALCHLOR Patient Brochure

VALCHLOR Patient Brochure

Covers helpful topics such as how to apply and store VALCHLOR and how to address common side effects. To provide to your patients in your office:

Download

Pay no more than $10.00 per prescription fill

Helsinn would like to support eligible patients who might be affected during the COVID-19 pandemic by temporarily waiving the $10 fee.

Helps eligible patients pay no more than $10 $0 per prescription fill.

*The VALCHLOR copay program is only available for US and Puerto Rico residents who are 18 or older and have commercial health insurance with copay/coinsurance exceeding $10 $0 per prescription fill. Patients ineligible for the VALCHLOR copay program include those enrolled in Medicare, Medicaid, VA/DoD (Tricare), the Indian Health Service, or any other federal- or state-funded healthcare program, or where prohibited by law. The VALCHLOR copay program is not prescription drug coverage or insurance. Helsinn Therapeutics, Inc. reserves the right to terminate or modify this program at any time or without notice. Other terms and conditions apply.

VALCHLOR Support logo

For more information, call 1-855-4-VALCHLOR (1-855-482-5245)

Additional support information

You can find additional information to help you educate your patients at the following websites:

Cutaneous Lymphoma Foundation: clfoundation.org

Lymphoma Research Foundation: lymphoma.org

Leukemia and Lymphoma Society: lls.org

Helsinn offers links to third-party websites that may assist you in locating other useful information. Helsinn does not control and is not responsible for the content of any linked third-party website, and hereby disclaims any and all liability and responsibility for these resources.


Reference:

  1. VALCHLOR [package insert]. Iselin, NJ: Helsinn Therapeutics US, Inc.; January 2020.
  2. Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial
    testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. Arch Dermatol. 2012;E1-E8.